Granules India is currently trading at Rs. 233.90, up by 7.50 points or 3.31% from its previous closing of Rs. 226.40 on the BSE.
The scrip opened at Rs. 228.85 and has touched a high and low of Rs. 240.00 and Rs. 227.60 respectively. So far 477683 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 240.00 on 10-Jul-2020 and a 52 week low of Rs. 84.25 on 23-Jul-2019.
Last one week high and low of the scrip stood at Rs. 240.00 and Rs. 205.00 respectively. The current market cap of the company is Rs. 5889.30 crore.
The promoters holding in the company stood at 42.86%, while Institutions and Non-Institutions held 24.71% and 32.43% respectively.
Granules India’s wholly owned subsidiary — Granules Pharmaceuticals Inc (GPI) is voluntarily recalling 12 lots of Metformin Hydrochloride Extended-Release Tablets USP, 750 mg, 100 and 500 count bottles within expiry to the consumer level due to the detection of N-Nitrosodimethylamine (NDMA) levels above the Acceptable Daily Intake Limit.
Granules’ test results showed NDMA levels above the FDA acceptable limit in 1 out of the 12 batches distributed to the US market. All other batches continue to remain within the specifications. Out of abundance of caution Granules Pharmaceuticals, Inc. has decided to voluntarily recall all 12 of the distributed lots within expiry of Metformin Hydrochloride Extended-Release Tablets USP, 750 mg from the market.
Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).
